Over six years, AUScelerate’s first Targeted Translation Research Accelerator program quietly reshaped the landscape for heart and diabetes care in Australia, unlocking $220 million in investment and propelling dozens of new treatments, technologies and support services closer to patients. …
AUScelerate programs channel major investment into heart and diabetes innovations
July 30, 2026 Latest NewsAustralian Biotech
Latest Video
New Stories
-
Rare autoimmune diseases impose a $1.2 billion annual burden on Australians
August 20, 2026 - - Latest News -
Recce advances pivotal diabetic foot infection trial with active antibiotic comparator arm
August 20, 2026 - - Latest News -
New Zealand researchers honoured for work tackling superbugs and blood cancer
August 20, 2026 - - Latest News -
Novo Nordisk backs care for rural health professionals in southern NSW
August 19, 2026 - - Latest News -
Opportunity #3 - finally deliver on the repeated claims of patient-centricity
August 19, 2026 - - Latest News -
Departmental restructure formally splits medicines financing from pharmacy services
August 19, 2026 - - Latest News -
Wesfarmers Health evolves its loyalty program with new Pulse Rewards
August 19, 2026 -